Pathophysiology of fluid administration in critically ill patients.
Antonio Messina, Jan Bakker, Michelle Chew...
https://pubmed.ncbi.nlm.nih.gov/36329266/Actively Recruiting
Led by Erasme University Hospital · Updated on 2026-06-04
88
Participants Needed
3
Research Sites
4 weeks
Total Duration
Researchers are evaluating the safety and feasibility of maintaining a near-neutral daily fluid balance compared to standard fluid management in critically ill adults with traumatic brain injury TBI. This international, multicenter, randomized phase II trial addresses uncertainty about optimal fluid therapy strategies to prevent complications like brain swelling or low blood volume, which can affect recovery and survival. The study aims to provide important preliminary evidence to guide future treatments for this serious condition. Participants admitted to intensive care units with TBI are randomly assigned within 48 hours to one of two groups. One group follows a protocol targeting a daily fluid balance close to zero 500 mL using restricted fluids, diuretics, and vasopressors over the first 5 days. The other group receives standard fluid management based on local clinical practices without a specific fluid balance goal. Both groups have their fluid inputs and outputs closely monitored while maintaining blood pressure and cerebral perfusion targets. During the study, participants will undergo close monitoring of fluid balance, organ function, blood pressure, and neurological status. Researchers will track outcomes including the feasibility of achieving neutral fluid balance, organ complications, use of medications like vasopressors and diuretics, days without organ support, mortality, and neurological recovery up to six months after randomization. The study involves detailed assessments during ICU stay and follow-up evaluations to understand the impact of fluid strategies on recovery and survival.
CONDITIONS
Feasibility and Safety of Targeting Neutral vs Liberal Fluid Balance in Traumatic Brain Injured Patients- LIMIT-TBI Trial
F
Fabio Silvio Taccone, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Erasme University Hospital
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 48 hours after ICU admission
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 5 days
Participants receive either a protocolized neutral fluid balance strategy targeting a daily fluid balance of 0 ± 500 mL for 5 days using restricted fluids, diuretics, and vasopressors, or standard fluid management according to local ICU practice and clinician judgment.
Daily monitoring and adjustments during ICU stay
Duration - Up to 6 months after randomization
Participants are monitored for organ complications, mortality, and neurological outcomes including assessments up to 180 days after randomization.
Visits at hospital discharge and at 180 days after randomization
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Antonio Messina, Jan Bakker, Michelle Chew...
https://pubmed.ncbi.nlm.nih.gov/36329266/Mauro Oddo, Daniele Poole, Raimund Helbok...
https://pubmed.ncbi.nlm.nih.gov/29500701/Marek Majdan, Dominika Plancikova, Alexandra Brazinova...
https://pubmed.ncbi.nlm.nih.gov/29253420/Nancy Carney, Annette M Totten, Cindy O'Reilly...
https://pubmed.ncbi.nlm.nih.gov/27654000/Guy L Clifton, Emmy R Miller, Sung C Choi...
https://pubmed.ncbi.nlm.nih.gov/11940738/Eveline Janine Anna Wiegers, Hester Floor Lingsma, Jilske Antonia Huijben...
https://pubmed.ncbi.nlm.nih.gov/34302787/Erasme University Hospital
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborating Sponsor